JP2023549017A5 - - Google Patents

Info

Publication number
JP2023549017A5
JP2023549017A5 JP2023518836A JP2023518836A JP2023549017A5 JP 2023549017 A5 JP2023549017 A5 JP 2023549017A5 JP 2023518836 A JP2023518836 A JP 2023518836A JP 2023518836 A JP2023518836 A JP 2023518836A JP 2023549017 A5 JP2023549017 A5 JP 2023549017A5
Authority
JP
Japan
Prior art keywords
coronavirus
protein
antigens
vaccine composition
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023518836A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023549017A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/058856 external-priority patent/WO2022103891A1/en
Publication of JP2023549017A publication Critical patent/JP2023549017A/ja
Publication of JP2023549017A5 publication Critical patent/JP2023549017A5/ja
Pending legal-status Critical Current

Links

JP2023518836A 2020-11-11 2021-11-10 多価担体および関連するワクチン組成物 Pending JP2023549017A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063112495P 2020-11-11 2020-11-11
US63/112,495 2020-11-11
PCT/US2021/058856 WO2022103891A1 (en) 2020-11-11 2021-11-10 Multivalent carriers and related vaccine compositions

Publications (2)

Publication Number Publication Date
JP2023549017A JP2023549017A (ja) 2023-11-22
JP2023549017A5 true JP2023549017A5 (cg-RX-API-DMAC10.html) 2024-11-14

Family

ID=81602587

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023518836A Pending JP2023549017A (ja) 2020-11-11 2021-11-10 多価担体および関連するワクチン組成物

Country Status (9)

Country Link
US (2) US12440553B2 (cg-RX-API-DMAC10.html)
EP (1) EP4243867A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023549017A (cg-RX-API-DMAC10.html)
KR (1) KR20230107304A (cg-RX-API-DMAC10.html)
CN (1) CN117098553A (cg-RX-API-DMAC10.html)
AU (1) AU2021378792A1 (cg-RX-API-DMAC10.html)
CA (1) CA3193843A1 (cg-RX-API-DMAC10.html)
IL (1) IL302176A (cg-RX-API-DMAC10.html)
WO (1) WO2022103891A1 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4182687A4 (en) * 2020-07-20 2024-09-11 Bio-Rad Laboratories, Inc. IMMUNOASSAY FOR SARS-COV-2 NEUTRALISING ANTIBODIES AND MATERIALS THEREFOR
WO2023102476A1 (en) 2021-12-02 2023-06-08 California Institute Of Technology Antibodies for coronaviruses and uses thereof
WO2024006532A2 (en) * 2022-06-30 2024-01-04 La Jolla Institute For Immunology Kari nanoparticle
CN117582492A (zh) * 2022-08-12 2024-02-23 上海市公共卫生临床中心 重组多价疫苗
JP2025529906A (ja) * 2022-08-22 2025-09-09 ザ ヘンリー エム ジャクソン ファンデイション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド コロナウイルスに対するワクチン
CN115894716B (zh) * 2022-11-23 2024-02-09 华中农业大学 一种重组融合蛋白纳米颗粒及其制备方法
CN117362447B (zh) * 2023-08-25 2024-04-09 广东省农业科学院农业生物基因研究中心 一种基于蛋白质偶联聚合体的生物发光酶联免疫分析方法
WO2025255622A1 (en) * 2024-06-13 2025-12-18 University Of Technology Sydney Method of vaccine prototyping

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7285289B2 (en) * 2002-04-12 2007-10-23 Nagy Jon O Nanoparticle vaccines
KR20070052273A (ko) * 2004-06-30 2007-05-21 아이디 바이오메디컬 코포레이션 오브 퀘벡 코로나바이러스 감염의 치료를 위한 백신 조성물
CA2608515A1 (en) * 2005-06-01 2007-05-10 Dow Global Technolgies Inc. Production of multivalent virus like particles
RU2628690C2 (ru) * 2015-11-06 2017-08-21 Общество С Ограниченной Ответственностью 'Фарминтерпрайсез' Аттенуированные гриппозные векторы для профилактики и/или лечения инфекционных заболеваний, а также для лечения онкологических заболеваний
US20190105282A1 (en) * 2016-03-23 2019-04-11 Che-Ming Jack Hu Thin-shell polymeric nanoparticles and uses thereof
US12194089B2 (en) * 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine

Similar Documents

Publication Publication Date Title
US20260137769A1 (en) Nucleic acid molecules and uses thereof
US11786590B2 (en) Rotavirus vaccines
US20240002449A1 (en) Respiratory syncytial virus (rsv) vaccine
Quach et al. Size-dependent neutralizing activity of gold nanoparticle-based subunit vaccine against dengue virus
JP2001500111A (ja) ブタの生殖病および呼吸病に対するポリヌクレオチドワクチン処方
JP2014522842A5 (cg-RX-API-DMAC10.html)
JP2000515521A (ja) イヌの症状、特に呼吸器および消化器症状に対するポリヌクレオチドワクチン製剤
JP2023532290A5 (cg-RX-API-DMAC10.html)
Kabiri et al. Robust mucosal and systemic responses against HTLV-1 by delivery of multi-epitope vaccine in PLGA nanoparticles
US20230136960A1 (en) Novel MRNA-Based COVID-19 Multi-Valent Vaccine and Methods of Scaled Production of the Same
CA3193843A1 (en) Multivalent carriers and related vaccine compositions
US20210187096A1 (en) Universal vaccine for viral diseases
CN116234587A (zh) 用于诱导免疫应答的免疫原性构建体、组合物和方法
US9943592B2 (en) Vaccine adjuvants from self-assembling peptides
KR20130044204A (ko) 점막 백신
ES2203436T3 (es) Composicion de vacuna a base de particulas.
CN116782927A (zh) 用于提高对抗冠状病毒的免疫力的方法及组合物
CN118765203A (zh) 一种新型阳离子佐剂组合物
US20100166808A1 (en) Method of Facilitating Intracellular Uptake or Transcellular Transport of Cargo Using Nanocarriers Containing Optimal Surface Densities of Integrin-Specific Ligands
Misra et al. Nano-adjuvants
TWI771546B (zh) 針對亨德拉(hendra)及尼帕(nipah)病毒感染之疫苗
JP2024518548A5 (cg-RX-API-DMAC10.html)
KR102731640B1 (ko) 리포펩타이드와 폴리(i:c) 아쥬반트를 포함하는 재조합 코로나-19 백신 조성물
JPWO2022230485A5 (cg-RX-API-DMAC10.html)
RU2023114392A (ru) Днк-кодированные наночастицы и способ их применения в качестве вакцины от коронавирусного заболевания 2019 (covid-19)